GB2452805A - Use of t-Bu QuinoxP - Google Patents

Use of t-Bu QuinoxP Download PDF

Info

Publication number
GB2452805A
GB2452805A GB0813271A GB0813271A GB2452805A GB 2452805 A GB2452805 A GB 2452805A GB 0813271 A GB0813271 A GB 0813271A GB 0813271 A GB0813271 A GB 0813271A GB 2452805 A GB2452805 A GB 2452805A
Authority
GB
United Kingdom
Prior art keywords
group
formula
compound
substituted
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0813271A
Other versions
GB0813271D0 (en
GB2452805B (en
Inventor
Tsuneo Imamoto
Kazuhiro Yoshida
Miwako Nishimura
Aya Koide
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiba University NUC
Nippon Chemical Industrial Co Ltd
Original Assignee
Chiba University NUC
Nippon Chemical Industrial Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiba University NUC, Nippon Chemical Industrial Co Ltd filed Critical Chiba University NUC
Publication of GB0813271D0 publication Critical patent/GB0813271D0/en
Publication of GB2452805A publication Critical patent/GB2452805A/en
Application granted granted Critical
Publication of GB2452805B publication Critical patent/GB2452805B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/18—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
    • B01J31/1845—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing phosphorus
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
    • C07C209/14—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups
    • C07C209/16—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups with formation of amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/04—Saturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/12—Ketones containing more than one keto group
    • C07C49/15—Ketones containing more than one keto group containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/38—Malonic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/023—Preparation; Separation; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/006—Palladium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/006—Palladium compounds
    • C07F15/0066—Palladium compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)

Abstract

A process of preparing an optically active allyl compound comprising asymmetrically coupling an allyl compound with an organic nucleophilic compound in the presence of a catalyst. Preferably, the nucleophile is a malonate compound or an amine. The preferred allylic compound is 1,3-diphenyl-2-propenyl acetate. The catalyst is preferably a transition metal complex compound having a phosphine ligand. The transition metal is preferably palladium. The phosphine ligand is preferably a 2,3-bis(dialkylphosphino)pyrazine derivative. The pyrazine derivative is preferably a quinoxaline derivative, more preferably a compound of formula (V): <EMI ID=1.1 HE=40 WI=39 LX=847 LY=1226 TI=CF> <PC>wherein * is an asymmetric centre, R6 and R7 are each independently an optionally substituted alkyl group, R8 and R9 are each independently selected from hydrogen, an optionally substituted alkyl group and a ring system, or R8 and R9 are taken together to form a fused ring.

Description

PROCESS OF PREPARING OPTICALLY ACTIVE ALLYL COMPOUND
Technical Field
This invention relates to a process of preparing an optically active allyl compound that is important as an intermediate for pharmaceuticals, agricultural s chemicals, or physiologically active substances, for example, very useful as an intermediate for synthesizing antibiotics.
Background Art
Processes that are known or thought to be useful for the production of an optically active allyl compound include (1) once synthesizing a racemic form of a desired ally! compound, followed by optical resolution using an optically active resolving agent or an enzyme, (2) starting with an asymmetric compound, or (3) using an asymmetric catalyst.
The process (1) which uses an optically active resolving agent requires an equivalent or more amount of a resolving agent relative to an ally! compound.
Moreover, complicated procedures such as crystallization, separation, and purification, are involved before obtaining an optically active allyl compound. The process (1) which uses an enzyme, while capable of yielding an allyl compound with relatively high optical purity, limits the type of a reaction substrate and the absolute configuration of a resulting allyl compound.
The process (2) is conceivable but problematic in that an optically active starting compound is not only expensive but must be used in a stoichiometric excess.
As the process (3), detailed researches have recently been done into catalytic asymmetric synthesis of an optically active allyl compound that can achieve high efficiency and asymmetric yield, as reported in Trost, B.M. & Van Vranken, D.L. Chem. ----Rev., 96, 395-422 (1996) and Trost, B.M. & Crawley, M.L., Chein. Rev., 103, 2921-2944 (2003). The techniques in this line are still under suL ------
Summary of the Invention
In the light of the above circumstances, it is an object of the invention to provide a process of preparing an optically active allyl compound at high efficiency in high asymmetric yield.
s As a result of extensive studies on catalytic asymmetric synthesis of an optically active allyl compound, the present inventors have found that asymmetric coupling reaction of an allyl compound with an organic nucleophilic compound in the presence of a catalyst gives a desired optically active allyl compound with the reduced number of steps at high efficiency in good asymmetric yield. The present invention has been reached based on this finding.
The invention provides a process of preparing an optically active allyl compound represented by formula (IU): Nu (III) R2 wherein R1, R2, R3, R4, and R5 each represent a hydrogen atom, an alkyl group, a substituted alkyl group, a cycloalkyl group, a substituted cycloalkyl group, an arailcyl group, a substituted arailcyl group, an aryl group, a substituted aryl group, an aliphatic heterocyclic group, a substituted aliphatic heterocyclic group, an aromatic heterocyclic group, or a substituted aromatic heterocyclic group; Nu represents a nucleophilic group selected from an a-ketocarbanion group, an amino group, and a substituted amino group; and the asterisk * indicates an asymmetric center.
or an optically active allyl compound represented by formula (IV): Nu R5 R17'R4 wherein R', R2, R3, R4, R5, Nu, and * are as defined above.
or a mixture of the compound of formula (HI) and the compound of formula (IV).
The process comprises asymmetrically coupling an allyl compound represented by formula (1): C') wherein R', R2, R3, R4, and R5 axe as defined above; and E represents a leaving group selected from a group comprising an oxygen atom and the group which is represented by R', R2, R3, R4, and R5 and is bonded to the oxygen atom; a halogeno group; a carbonic ester group; a sulfonic ester group; a phosphonic ester group; a phoshoric ester group; and a carboxylic ester group.
with an organic nucleophilic compound represented by formula (II): Nu-H (II) wherein Nu is as defined above.
in the presence of a catalyst.
Detailed Descnption of the Invention -he aiIyfco otiiidth in &üsedás a St teriatin-the-process-of-the-invention is represented by formula (I). The product obtained by the process of the invention is the optically active allyl compound represented by formula (III), the optically active allyl compound represented by formula (IV), or a mixture thereof. The groups represented by R1, R2, R3, R4, and R5 in formulae (I), (Ill), and (IV) will be described.
The term "ailcyl group" includes straight-chain or branched ailcyl groups having 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, 2-propyl, n-butyl, 2-butyl, isobutyl, tert-butyl, n-pentyl, 2-pentyl, tert-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-hexyl, 3-hexyl, tert-hexyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, and 5-methylpentyl.
The term "substituted alkyl group" includes the above recited alkyl groups at least one hydrogen atom of which is displaced with a substituent, such as an ailcyl group, a cycloalkyl group, an ailcoxy group, a halogen atom, an amino group, or a protected amino group. Any protective group known for the protection of an amino group can be used. Examples of the amino protective group are described, e.g., in Protective Groups in Organic Synthesis, 2nd Ed., John Wiley & Sons, Inc. Examples of useful amino protective groups include an alkyl group, a cycloallcyl group, an aralkyl group, an acyl group, and an alkyloxycarbonyl group.
The term "cycloallcyl group" includes a cycloalkyl group having 3 to 16 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 2-methylcyclopentyl, 3-methylcyclopentyl, cycloheptyl, 2-methylcyclohexyl, 3-methylcyclohexyl, and 4-methylcyclohexyl. The term "cycloalkyl group" also includes a polycyclic alkyl group, such as menthyl, bomyl, norbornyl, or adamantyl.
The substituted cycloalkyl group includes the above described cycloalicyl groups at least one hydrogen atom of which is displaced with a substituent such as an alkyl group, a cycloalkyl group, an alkoxy group, a halogen atom, an amino group or a protected amino group.
-The term "arailcyl group" includes aralkyl groups having 7 to 12 carbon atoms, such as benzyl, 2-phenylethyl, 1-phenyipropyl, 2-pheylrcy1, ènlpl, -- 1 -phenylbutyl, 2-phenylbutyl, 3-phenylbutyl, 4-phenylbutyl, I -phenylpentyl, 2-phenylpentyl, 3-phenylpentyl, 4-phenylpentyl, 5-phenylpentyl, I -phenyihexyl, 2-phenyihexyl, 3-phenyihexyl, 4-phenylhexyl, 5-phenylhexyl, and 6-phenyihexyl.
The substituted aralkyl group includes the above described aralkyl groups at least one hydrogen atom of which is displaced with a substituent such as an alkyl group, a cycloalkyl group, a halogenated alkyl group, an alkoxy group, a halogen atom, an amino group, or an allcyl-substituted amino group.
The term "aryl group" includes aryl groups having 6 to 14 carbon atoms, such as phenyl, naphthyl, and anthryl.
The substituted aryl group includes the above described aryl groups at least one hydrogen atom of which is displaced with a substituent such as an alkyl group, a cycloalkyl group, a halogenated alkyl group, an alkoxy group, a halogen atom, an amino group, or an alkyl-substjtuted amino group and the above described aryl groups adjacent two hydrogen atoms of which are displaced with a substituent such as an alkylenedioxy group.
The "aliphatic heterocyclic group" is preferably 5-or 6-membered. The aliphatic heterocyclic group includes one containing 1 to 3 hetero atoms such as nitrogen, oxygen, and sulfur atoms. Examples of the aliphatic heterocyclic group include pyrrolidy-2-one, piperidino, piperazinyl, morpholino, tetrahydrofuryl, and tetrahydropyranyl.
The term "substituted aliphatic heterocyclic group" includes the above described aliphatic heterocyclic groups at least one hydrogen atom of which is displaced with a substituent such as an alkyl group, a cycloalkyl group, a halogenated alkyl group, an alkoxy group, or a halogen atom.
The term "aromatic heterocyclic group" preferably includes 5-or 6-membered, monocyclic or polycyclic aromatic heterocyclic rings containing 1 to 3 hetero atoms such as nitrogen, oxygen, and sulfur atoms. Examples of the aromatic heterocyclic group include pyridyl, imidazolyl, thiazolyl, flirfuryl, pyranyl, fuzyl, benzofuryl, and thienyl. --_-The "substituted aromatic heterocyclic group" includes the above described aromatic heterocyclic groups at least one hydrogen atom of which* is displaced with a substituent such as an alkyl group, a cycloalkyl group, a halogenated alkyl group, an alkoxy group, or a halogen atom.
In formulae (I), (Ill), and (LV), R', R2, R3, R4, and R5 may be the same or different. They may be independent of each other, or two or more of them may be crosslinked to each other.
In formula (I), E represents a leaving group. Specifically E represents a group comprising (a) a hydrogen atom or the group represented by R', R2, R3, R4, and R5, and (b) an oxygen atom. In this case E is bonded to the carbonyl group via the oxygen atom. E also represents a halogeno group, a carbonic ester group, a sulfonic ester group, a phosphonic ester group, a phoshoric ester group, and a carboxylic ester group.
Examples of the group comprsing the hydrogen atom or the group as represented by R', R2, R3, R4, or R5 and an oxygen atom include a hydroxyl group, a methoxy group, an ethoxy group, a phenyloxy group, a benzyloxy group, and a p-methoxybenzyloxy group. Examples of the halogeno group are fluoro, chioro, bromo, and iodo. Examples of the carbonic ester are methyl carbonate, ethyl carbonate, and tert-butyl carbonate. Examples of the sulfonic ester are a methanesulfonate a benzenesulfonate, a p-toluenesulfonate, and a trifluoromethanesulfonate Examples of the phosphonic ester are methyl phosphonate, ethyl phosphonate, and phenyl phosphonate. Examples of the phosphoric ester are methyl phosphate, ethyl phosphate, and phenyl phosphate. Examples of the carboxylic ester include an acetate, a propionate, an oxalate, and a benzoate.
The organic nucleophilic compound represented by formula (II) that is used in the coupling reaction of the allyl compound of formula (I) is described below. The group represented by Nu in formula (H) is a nucleophilic group selected from an a-ketocarbanjon group, an amino group, and a substituted amino group.
Examples of the a-ketocarbanjon include organic compounds having a structure of formula as described below. Examples of such organic compounds include acetone ci-dehydro anion, ethyl acetate a-dehydro anion, and diethyl malonate a-dehydro anion.
II -c-c
The term "substituted amino group" refers to an amino group at least one hydrogen of which is displaced with a substituent such as an alkyl group, a cycloalkyl group, a halogenated alkyl group, an alkoxy group, or a halogen atom. The term "substituted amino group" includes a cyclic amino group, such as a morpholino group, a pyrrolidino group, and a 3-oxazolin-2-on-1-yl group.
The coupling reaction between the allyl compound of formula (1) and the organic nucleophilic compound of formula (U) is carried out in the presence of a catalyst. In the present invention, a transition metal complex compound having a phosphine ligand is preferably used as a catalyst.
It is particularly preferred to use, as a phosphine ligand, a 2,3-bis(dia1Iphosphno)pyrine derivative represented by formula (V): R6 R7 ::x:x' R7 R6 wherein * is as defined above; R6 and R7 each represent -----ancLR! --each have the same meaning as R', R2, R3, R4, and R5, or R8 and R9 are taken together to form a fused ring.
In formula (V), the alkyl group and the substituted alkyl group as R6 and R7 are exemplified by the same examples as recited for R', R2, R3, R4, and R5. R6 and R7 may be the same or different. Although R6 and R7 may be independent of each other or crosslinked to each other, it is essential to select R6 and R7 so as to result in asymmetry on the phosphorus atom or to make the phosphorus atom constitute a point of the symmetry plane of axial asymmetry.
In order to effectively induce asymmetry on the phosphorus atom, it is preferred that R6 and R7 are selected so as to make a large difference in three-dimensional bulkiness therebetween. Examples of a preferred combination of R6 and R7 are a combination of a methyl group and a tert-butyl group and a combination of a methyl group and an adamantyl group.
In order to make the phosphorus atom constitute a point of the symmetry plane of axial asymmetry, it is preferred that the moieties of R6 and R7 providing the asymmetry are as close as possible to the phosphorus atom so as to effectively induce the asymmetry. This is exemplified by a configuration in which R6 and R7 are crosslinked to each other, and an atomic group including the crosslinked moiety and the phosphorus atom is 2,5-dimethylphospholane.
The group represented by R8 and R9 in formula (V) is then described. As stated, R8 and K9 have the same meaning as R', R2, R3, R4, and R5. R8 and R9 may be the same or different. R8 and K9 may be taken together to form a fused ring.
Examples of the fused ring include a benzene ring, a naphthalene ring, a phenanthrene ring, a methylenedioxy ring, an ethylenedioxy ring, and a cyclohexane ring.
It is particularly preferred that R8 and R9 are taken together to form a benzene ring. In this case, the pyrazine derivative represented by formula (V) is a 2,3-bis(diaIlcylphosphjno)qoxalj derivative represented by formula (Vi): R6 R7 Rw-(t R7 R6 wherein R6, R7, and the asterisk * are as defined above; In formula (VI), the substituent represented by R'° is a monovalent substituent.
Examples of the monovalent substituent include an alkyl group, a cycloalkyl group, a halogenated alkyl group, an alkoxy group, a halogen atom, an amino group, a protected amino group, and a nitro group. The benzene ring may have one or more than one substituents R'°. When there are two or more substituents R'°, they may be either the same or different.
Examples of the pyrazine derivative of formula (V) having asymmetry introduced at the phosphorus atom are shown below.
t-Bu Me Ad Me 0(1; Me t-Bu Me Aci (a) (b) (a): (S,S)-2,3-Bis(tertbuty1methy1phosphjno)quoxa] or (b): or (R)-2Bis(adamanethy1phosphjflo)qujnoxaljne Examples of the pyrazine derivative of formula (V) in which the phosphorus atom constitutes a point of symmetry plane of axial asymmetry as shown below.
(c) (d) (c): 2,3-Bis[(R,R)-2,5-dimethylphospholano]quinoxaline (d): 2,3-Bis[(S,S)-2,5-dimethylphospholano]quinoxaline The pyrazine derivatives of formula (V) including the quinoxaline derivatives of formula (VI) can be prepared in accordance with the process disclosed in commonly assigned U.S. Patent Application 2007/0021610A1, the disclosure of which is incorporated herein by reference.
The pyrazine derivative of formula (V) including the quinoxaline derivative of formula (VI) reacts with a transition metal to form a complex compound, which can be used as a catalyst for asymmetric synthesis. Examples of the transition metal with which to form a complex include rhodium, ruthenium, iridium, palladium, nickel, and iron. Preferred of them are the group VIII elements, such as rhodium, ruthenium, iridium, palladium, and nickel. Palladium is particularly preferred. A palladium complex having the pyrazine derivative of formula (V) as a ligand can be prepared by, for example, mixing a pyrazine derivative of formula (V) and a palladium compound having an allyl compound coordinated to a palladium atom, e.g., [PdCI(Tf-C3H5)]2.
---The catalyst comprising the transition metal complex compound is preferably used in an amount of 0.0001 to 100 mol%, more preferably 0.001 to 10 rnol%, based on ---the reaction substrate. To promote the reaction moderately while suppressing the amount of the catalyst to be used, an even more preferred amount of the catalyst to be used is 0.02 to 5 mol%.
II
To accelerate smooth progress of the asymmetric coupling reaction, a base may be used. Examples of useful bases include, but are not limited to, N,O-bis(trimethylsjlyl)acetamjde (BSA), potassium acetate, and a mixture thereof.
The asymmetric coupling reaction is usually carried out in a solvent commonly employed in general organic chemical reactions, such as toluene, hexane, tetrahydrofliran (THF), diethyl ether, dioxane, acetone, ethyl acetate, chlorobenzene, dimethylformam.ide (DMF), acetic acid, and water. Preferred solvents are methanol, ethanol, and dichioromethane.
The amount of the solvent to be used is decided appropriately, taking into consideration the fluidity of the reaction mixture during the reaction and the effects the solvent exerts on the reaction. Where the reaction proceeds well without a solvent, for example, when the reactant mixture to be reacted is a low-viscosity, homogeneous fluid with no aid of a solvent, it is not necessary to use a solvent.
The asymmetric coupling reaction temperature is preferably -80°C to 150°C, more preferably 0°C to 120°C in which range the reaction is promoted while suppressing a side reaction and raceinization.
The asymmetric coupling reaction is preferably carried out for a period of from one minute to one month, more preferably a period of from 3 hours to 3 days, which period is adequate for completion of the reaction.
The asymmetric coupling reaction according to the present invention generally results in the formation of the optically active allyl compound of formula (III). When rearrangement of the leaving group occurs during the reaction, the optically active allyl compound of formula (IV) is obtained. When it is desired to selectively obtain either one of them, reaction conditions that will result in an increased selectivity to a desired -coipound are established through proper selection of the catalyst, the solvent, and the like. Otherwise, a mixture of the two compounds as obtained can be subjected to crystallization, distillation, column chromatography, preparative HPLC, and so forth to isolate a desired optically active allyl compound.
The optically active allyl compound synthesized by the process of the invention can be used in the form of a reaction mixture as obtained. If desired, the reaction mixture may be subjected to usual work-up and purification procedures such as solvent removal, liquid- liquid separation, crystallization, distillation, sublimation, and column s chromatography.
The preparation process of the invention may be performed either batchwise or continuously.
The optically active ally! compound obtained by the process of the invention is used as an intermediate for pharmaceuticals, agricultural chemicals, and physiologically active substances. For example, it is useful as an intermediate for synthesis of antibiotics.
Examples
The present invention will now be illustrated in greater detail with reference to Examples, but it should be understood that the invention is not construed as being limited thereto.
All the synthesis operations in Examples were carried out using thoroughly dried glassware. The reaction was performed in an argon or nitrogen atmosphere. A commercially available phosphine ligand, (R,R)-2,3-bis(tert-butylmethylphospjijno)..
quinoxaline ((R,R)tBuQuinoxp*), from Sigma-Aldrich Japan, was used as such.
The solvent and the metal compound such as [PdCl(13-C3H5)]2 were general reagents.
NMR spectrum measurement was performed using an NMR spectrometer from JEOL, Ltd. (H: 300 MHz; 3C: 75.4 MHz; 31P: 121.4 MHz). Tetramethylsilane (H) was used as an internal standard. GC analysis was performed using GC-l4B FID detector from Shimadzu Corp. Mass spectrometry was conducted using GC-MS from -Shimadzu Cor ------
Example I
Synthesis of dimethyl (S)-cc-( 1,3-diphenyl-2-propen-1 -yl)malonate In 0.5 ml of dichioromethane were suspended 0.9 mg (2.5 j.tmol) of [PdCI(i3-C3H5)}2 and 1.8 mg (5.5 iimol) of (R,R)tBu.Qujnoxp* (1), followed by stirring at room temperature for 10 to 30 minutes. To the resulting solution were added a solution of 126 mg (0.50 mmol) of l,3-diphenyl-2-propenyl acetate in 1.5 ml of dichloromethane, 171 il (1. 50 mmol) of dimethyl malonate, 367 j.tl (1.50 mmol) of N,O-bis(trimethylsj1yl)acenjde (BSA), and a trace amount of potassium acetate.
The reaction system was stirred at room temperature for 1 hour. The reaction mixture was diluted with diethyl ether, and a saturated aqueous solution of ammonium chloride was added to stop the reaction. The resulting mixture was extracted with diethyl ether, and the organic layer was washed with a sodium chloride aqueous solution. The organic layer was dried over anhydrous sodium sulfate. Any volatile matter was evaporated off, and the residue was purified by silica gel column chromatography.
Examples 2 to 13
Various optically active allyl compounds were synthesized in the same manner as in Example 1, except for altering the nucleophilic compound (Nu-H), additive, and so forth as shown in Table 1 below. The results obtained are shown in Table I together with the results of Example 1. Unless otherwise specified, the allylalkylation reaction system was I,3-diphenyl-2-propenyj acetate (3)/malonic ester or acetylacetoncfBSAJtBuQujnoxp* (1)/[PdC1(3-C3H5)]2/CH2C12 = 0.50 mmol/ 1.5 minolll.5 mmo]J0.0055 mmolJO.0025 mmol/2.0 nil; 1 mol% Pd, and the allylamination reaction system was l,3-diphenyl-2-propenyl acetate (3)/ainine/BSA/ tBu.QuinoxP* (1)/[PdCI(13-C3fl5)]2/CR2CI2 = 0.50 mmolJl.5 mmolJl.5 mmoll 0.011 mmoIJO.0050 mmoJJ2.0 nil; 2 mol% Pd.
Table 1
Synthesis of Optically Active Allyl Compound t-Bu Me OAc [PdCI(113.C3H&]2 /1 Nu N fr + Nu-H Additive, CH2C1, PV-"Ph XNP temp. Me t-Bu * 1 1 Example Nu.H Additive Catalyst T(e;.
_________ H2C(COOMe)2 KOAc+BSA I r.t. 1 85 (4a) 92 (S) 2 HCCH3(COOMe)2 KOAc+BSA I r.t. 1 97 (4b) 95(R) 3 HC(n-Bu)(COOEt)2 KOAC-1-BSA I ri 1 87 (4c) 92 4 HC(C}1zPh)(COOEt) KOAc+BSA I r.t. 48 93 (4d) 90 HC(N}ICHO)(COOE*)2 KOAc+BSA 1 r.L 26 94 (4e) 91 6 HC(NHACXCOOEt)Z KOAc-I-BSA 1 r.t. 27 83 (41) 91 CR) 7 H2C(COMe)2 KOAc+BSA I r.t. 1 88 (4g) 95 (S) 8 HCCH3(COOMc)2 KOAc+BSA 3 -50°C 20 92 (4b) 98.7 (R) 9 morpholine -2 r.t. 13 69 (4h) 78 rnorpholine BSA 2 r.t. 13 94 (4h) 89 11 pro1idine BSA 2 r.t. 20 81 (4i) 90 (R) 12 butylamine BSA 2 r.L 63 >99 (4j) 73 _________ cyclohexylamine BSA 4 r.t. 48 96 (4k) 89 Note: *1: isolation yield *2: Determined by chiral HPLC *3: Determined by comparing the chiral HPLC results with literature data.
*4: Reaction system was 1,3-diphenyl-2-propenyl acetate (3)/methyl malonate/BSA/t-Bu-Qujnoxy * (1)/[PdCI(i3-C3H5)]z/CJ12C12 = 0. 50 tnmol/ 1.5 mmol/1.5 mmoIiO.016 mmolIO.0075 nunoll2.O ml; 3 mol% Pd *5: Reaction system was l,3-diphenyl-2-propenyl acetate (3)/cyclohexylamine/ -------BSAJtBuQuinox*(4)/[pdCl(fl3..C3fls)J2/CH2C12_0j0j,moJ/j5noJJ ---1. 5 mmoJJOO2l mmolJO.O10 mrnol/1.O ml; 4 mol% Pd According to the process of the present invention, an optically active ally! compound with high optical purity can be produced with the reduced number of steps using a small amount of a catalyst, and the catalyst used in the process achieves excellent catalytic activity and enantio-. and diastereoselectivity. The optically active allyl compound obtained by the process of the invention is important as an intermediate for pharmaceuticals, agricultural chemicals, and physiologically active substances.
For example, it is very useful as an intermediate for synthesizing antibiotics. Thus, the present invention is of very high industrial utility.

Claims (5)

  1. WHAT IS CLAIMED IS: 1. A process of preparing an optically active allyl compound represented by formula (III): R1 Nu R2R5 (III) wherein R', R2, R3, R4, and R5 each represent a hydrogen atom, an alkyl group, a substituted alkyl group, a cycloalkyl group, a substituted cycloalkyl group, an aralkyl group, a substituted aralkyl group, an aiyl group, a substituted aryl group, an aliphatic heterocyclic group, a substituted aliphatic heterocyclic group, an aromatic heterocyclic group, or a substituted aromatic heterocyclic group; Nu represents a nucleophilic group selected from an cz-ketocarbanion group, an amino group, and a substituted amino group; and the asterisk * indicates an asymmetric center, or an optically active allyl compound represented by formula (IV) : Nu R5 R1"f'R4 wherein R1, R2, R3, R4, R5, Nu, and * are as defined above, or a mixture of the compound of formula (Ill) and the compound of formula (IV), the process comprising asymmetrically coupling an allyl compound represented by formula (I): R2(''R5 (I) wherein R', R2, R3, R4, and R5 are as defined above; and E represents a leaving group selected from a group comprising an oxygen atom and the group which is represented by R', R2, R3, R4, and R5 and is bonded to the oxygen atom; a halogeno group; a carbonic ester group; a sulfonic ester group; a phosphonic ester group; a phoshoric ester group; and a carboxylic ester group, with an organic nucleophjljc compound represented by formula (Ii): Nu-H (II) wherein Nu is as defmed above, in the presence of a catalyst.
  2. 2. The process according to claim 1, wherein the catalyst is a transition metal complex compound having a phosphine ligand.
  3. 3. The process according to claim 2, wherein the transition metal complex compound is a palladium compound.
  4. 4. The process according to claim 2, wherein the phosphine ligand is a pyrazine derivative represented by formula (V): R6 R7 R8 N flrP* 9.A%
    R N R7 R6
    -Whreiii*1s as defined-above;-R and-R1eacb-represent ------------an alkyl group or a substituted alkyl group; R8 and R9 each have the same meaning as R', R2, R3, R4, and R5, or R8 and R9 are taken together to form a fused ring. I ?
  5. 5. The process according to claim 4, wherein the pyrazine derivative represented by formula (V) is a quinoxaline derivative represented by formula (Vi): R6 R7 R1O4JcEP. (VI) RT R6 wherein R6, R7, and * are as defined above;
GB0813271.4A 2007-07-26 2008-07-18 Process of preparing optically active allyl compound Expired - Fee Related GB2452805B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007195234 2007-07-26

Publications (3)

Publication Number Publication Date
GB0813271D0 GB0813271D0 (en) 2008-08-27
GB2452805A true GB2452805A (en) 2009-03-18
GB2452805B GB2452805B (en) 2012-03-21

Family

ID=39737347

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0813271.4A Expired - Fee Related GB2452805B (en) 2007-07-26 2008-07-18 Process of preparing optically active allyl compound

Country Status (3)

Country Link
JP (1) JP2009046469A (en)
DE (1) DE102008033164B4 (en)
GB (1) GB2452805B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104119382A (en) * 2014-07-15 2014-10-29 同济大学 1,3-disubstituted-allylphosphine oxide compounds and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1438227A (en) * 2003-03-14 2003-08-27 中国科学院上海有机化学研究所 Novel phosphine ligand containing chiral four-membered ring base, its synthesizing method and use
US20070066825A1 (en) * 2003-05-22 2007-03-22 Ulrich Scholz Chiral ligands and their transition metal complexes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4400837A1 (en) * 1994-01-14 1995-07-20 Basf Ag Process for the preparation of n-butyraldehyde and / or n-butanol
FR2775975B1 (en) * 1998-03-16 2001-10-19 Rhodia Chimie Sa 1-PHOSPHANORBORNADIENES
JP2002537400A (en) * 1999-02-23 2002-11-05 ザ ユニバーシティ オブ ワーウィック Chiral diazaphospholidine ligand
JP2001328993A (en) * 2000-03-14 2001-11-27 Kuraray Co Ltd Optically active phosphine compound
KR101189935B1 (en) * 2004-05-11 2012-10-12 홍콩 폴리테크닉 유니버시티 Ligands for transition metal catalyzed reactions
JP2008538585A (en) * 2005-04-22 2008-10-30 ダウ グローバル テクノロジーズ インコーポレイティド Asymmetric hydroformylation process
JP4500289B2 (en) * 2005-07-25 2010-07-14 国立大学法人 千葉大学 2,3-bis (dialkylphosphino) pyrazine derivative, method for producing the same, and metal complex having the derivative as a ligand
US7608709B2 (en) * 2005-07-25 2009-10-27 National University Corporation Chiba University 2, 3-bis(dialkylphosphino)pyrazine derivative, process of producing the same, and metal complex having the same as ligand

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1438227A (en) * 2003-03-14 2003-08-27 中国科学院上海有机化学研究所 Novel phosphine ligand containing chiral four-membered ring base, its synthesizing method and use
US20070066825A1 (en) * 2003-05-22 2007-03-22 Ulrich Scholz Chiral ligands and their transition metal complexes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
European Journal of Organic Chemistry, Vol. 10, 2005, ( Tsarev, Vasily N. et al), pages 2097-2105, ISSN: 1434-193X *
Synlett, Vol. 8, 2005, (Braga, Antonio L. et al), pages 1331-1333, ISSN: 0936-5214 *
Tetrahedron Letters, Vol. 46, No. 20, 2005, (Chelucci, Giorgio; Orru, Gianmauro), pages 3493-3496, ISSN: 0040-4039 *
Tetrahedron: Asymmetry, Vol 15, No. 14, 2004, (Cozzi, Pier Giorgio et al), pages 2235-2239, ISSN: 0957-4166 *
Tetrahedron: Asymmetry, Vol. 16, No. 12, 2005, (Nakano, Hiroto; Takahashi, Kouichi; Fujita, Reiko), pages 2133-2140, ISSN: 0957-4166 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104119382A (en) * 2014-07-15 2014-10-29 同济大学 1,3-disubstituted-allylphosphine oxide compounds and preparation method thereof

Also Published As

Publication number Publication date
JP2009046469A (en) 2009-03-05
GB0813271D0 (en) 2008-08-27
GB2452805B (en) 2012-03-21
DE102008033164B4 (en) 2012-04-26
DE102008033164A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
EP0916637B1 (en) Process for preparating optically active compounds
Hayashi et al. A new optically active monodentate phosphine ligand,(R)-(+)-3-diphenylphosphino-3′-methoxy-4, 4′-biphenanthryl (MOP-phen): preparation and use for palladium-catalyzed asymmetric reduction of allylic esters with formic acid
CN112824422B (en) Chiral ferrocene-indole diphosphine ligand as well as preparation method and application thereof
Xie et al. Design and synthesis of new chiral pyridine–phosphite ligands for the copper-catalyzed enantioselective conjugate addition of diethylzinc to acyclic enones
CA2889650C (en) Process and intermediates for preparing lacosamide
KR101130818B1 (en) Method for preparing chiral amino acid from azlactones using bifunctional bis-cinchona alkaloid thiourea organo catalysts
DK2958893T3 (en) Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide
US8076480B2 (en) Process of preparing optically active allyl compound
US7649117B2 (en) Process of preparing optically active β-hydroxycarboxylic acid derivative
GB2452805A (en) Use of t-Bu QuinoxP
CN102309984A (en) Phosphoric acid amide bifunctional catalyst and synthetic method thereof
JP5569938B2 (en) Pyrrolidine derivative and method for producing the same
JP3547590B2 (en) Asymmetric zirconium catalyst
US5756799A (en) Chiral phosphinites
CN114426564B (en) Chiral ferrocene phosphine-1, 2-diphenyl ethylenediamine ligand and preparation method and application thereof
JP2003261490A (en) NEW CHIRAL ZIRCONIUM CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ANTI-alpha-METHYL-beta-AMINOCARBONYL COMPOUND
US8013171B2 (en) Axially asymmetric ester compound and production method thereof
AU2009224059A1 (en) Catalytic process for asymmetric hydrogenation
KR101237531B1 (en) A catalyst for preparation of all-carbon quaternary stereocenter compound and a method for preparation thereof
US8222433B2 (en) Axially asymmetric phosphorus compound and production method thereof
US20040063999A1 (en) Process for the production of optically active amino alcohols
KR20240022317A (en) Method for preparing chiral aldol reaction product of nitroso compounds using chiral catalyst compounds
US20040186314A1 (en) Process for the preparation of enantiomerically enriched n-acyl-beta-amino acid derivatives by enantioselective hydrogenation of the corresponding (z)-enamides
JP5981747B2 (en) Azadirs-Alder reaction catalyst and method for producing tetrahydropyridine compound using the same
CN115025814A (en) Universal chiral catalyst and preparation method thereof

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20130718